Avène Mineral Light Mattifying Sunscreen Lotion
Pierre Fabre Dermo-Cosmetique introduces the Avène Mineral Light Mattifying Sunscreen Lotion with SPF 50+. This sunscreen offers broad-spectrum sun protection without irritation while delivering oil control and providing a natural mattifying finish for oily and acne-prone skin. This product absorbs quickly into the skin and can be worn under makeup. Avène Mineral Light Mattifying Sunscreen Lotion should be applied to the face 15 minutes prior to sun exposure and reapplied after 80 minutes of swimming or sweating, immediately after towel drying, or every 2 hours. For more information, visit www.aveneusa.com.
Ducray Anacaps Activ+ Dietary Supplement
Pierre Fabre Dermo-Cosmetique introduces Ducray Anacaps Activ+ Dietary Supplement, a once-daily capsule that contains zinc, molybdenum, iron, and selenium. This supplement targets factors that trigger sudden hair loss, including seasonal changes, stress, and diet. It also targets chronic hair loss with genetic, hormonal, and vascular causes. This formula provides essential nutrients needed to promote healthy hair growth from within, preserve hair density, and maintain the strength and vitality of hair. This supplement also is used for weak, devitalized nails and has a vegan formula with good digestive tolerance. For more information, visit www.ducray.com/en-us/.
Luzu
Ortho Dermatologics receives US Food and Drug Administration approval of the Supplemental New Drug Application to expand the use of Luzu (luliconazole) Cream 1% to pediatric patients. This new indication is for the topical treatment of interdigital tinea pedis and tinea cruris in patients 12 years of age and older and for tinea corporis in patients 2 years of age and older. Luzu is a topical azole antifungal agent with a 1-week, once-daily treatment regimen with results available 3 weeks post-treatment. Luzu previously was approved for use in adult patients. For more information, visit www.luzurx.com/HCP.
Xeljanz and Xeljanz XR
Pfizer Inc announces US Food and Drug Administration approval of twice-daily Xeljanz 5 mg and once-daily Xeljanz XR extended release 11 mg (tofacitinib) for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs. Xeljanz and Xeljanz XR are Janus kinase inhibitors that previously were approved for the treatment of rheumatoid arthritis. For more information, visit www.xeljanz.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@mdedge.com.